[French recommendations for malignant pheochromocytomas and paragangliomas by the national ENDOCAN-COMETE network].
Recommandations du réseau national ENDOCAN-COMETE pour la prise en charge des phéochromocytomes et paragangliomes métastatiques.
Diagnosis
Diagnostic
Follow-up
Malignant paraganglioma
Malignant pheochromocytoma
Paragangliomes métastatiques
Phéochromocytomes métastatiques
Recommandations
Recommendations
Suivi
Traitement
Treatment
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
22
12
2022
revised:
22
05
2023
accepted:
05
06
2023
pubmed:
13
8
2023
medline:
13
8
2023
entrez:
12
8
2023
Statut:
ppublish
Résumé
Pheochromocytomas and paragangliomas are rare neuroendocrine tumors, developed respectively in the adrenal medulla and in extra-adrenal locations. Their malignancy is defined by the presence of distant metastases. Forty percent of them are inherited and can be part of different hereditary syndromes. Their management is ensured in France by the multidisciplinary expert centers of the ENDOCAN-COMETE national network "Cancers of the Adrenal gland", certified by the National Cancer Institute and discussed within multidisciplinary team meetings. The diagnostic and therapeutic work-up must be standardized, based on an expert analysis of clinical symptoms, hormonal biological secretions, genetics, morphological and specific metabolic imaging. In the context of a heterogeneous survival sometimes beyond seven to ten years, therapeutic intervention must be justified. This is multidisciplinary and relies on surgery, interventional radiology, external or internal radiotherapy and medical treatments such as sunitinib or dacarbazine and temodal chemotherapy. The personalized approach based on functional imaging fixation status and genetics is progressing despite the extreme rarity of this disease.
Identifiants
pubmed: 37573200
pii: S0007-4551(23)00297-7
doi: 10.1016/j.bulcan.2023.06.002
pii:
doi:
Types de publication
English Abstract
Practice Guideline
Langues
fre
Sous-ensembles de citation
IM
Pagination
1063-1083Informations de copyright
Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.